ArticleAbdominal radiology (New York)2024
Inter-reader agreement of pancreatic adenocarcinoma resectability assessment with photon counting versus energy integrating detector CT.
Article in Abdominal radiology (New York), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 18 citations in OpenAlex.
- Practical applications of photon-counting CT in oncology: an organ-based pictorial review.Insights into imaging · 2026Article
- Photon-counting CT-guided precise subtotal resection of pancreatic head benign tumor with complete protection of pancreaticoduodenal arcades.Hepatobiliary surgery and nutrition · 2026Article
- Scan Range and Radiation Dose of the Ultra-High-Resolution Series in Pancreatic Photon-Counting Detector CT: A Prospective Two-Group Comparison of an Ultra-Low-Dose Planning Series.Diagnostics (Basel, Switzerland) · 2026Article
- Photon-counting CT for hepato-bilio-pancreatic imaging: a qualitative head-to-head comparison with third-generation dual-source CT: preliminary results.La Radiologia medica · 2026Article
- CT-based vascular invasion in pancreatic ductal adenocarcinoma compared with intraoperative and histological findings.Insights into imaging · 2026Article
- Clinical benefits and current challenges of photon-counting detector CT in vascular imaging.Radiology advances · 2026Review
- Intraindividual comparison of photon-counting detector CT and third-generation dual-source energy-integrating detector CT in multiphasic contrast-enhanced abdominal CT.Scientific reports · 2026Article
- Photon-counting CT for pancreatic cancer: advancing precision imaging and virtual surgical navigation.Journal of pancreatology · 2026Review
- Photon-counting detector CT in oncology: a new era of cancer imaging.Insights into imaging · 2026Review
- Applications of photon-counting CT in oncologic imaging: A systematic review.World journal of radiology · 2025Article
- Optimal virtual monoenergy for the detection of pancreatic adenocarcinoma during the pancreatic parenchymal phase on photon counting CT.Abdominal radiology (New York) · 2025Article
- Photon-counting CT: technical features and clinical impact on abdominal imaging.Abdominal radiology (New York) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the inter-reader agreement of pancreatic adenocarcinoma resectability assessment at pancreatic protocol photon-counting CT (PCCT) with conventional energy-integrating detector CT (EID-CT).
methodsA retrospective single institution database search identified all contrast-enhanced pancreatic mass protocol abdominal CT performed at an outpatient facility with both a PCCT and EID-CT from 4/11/2022 to 10/30/2022. Patients without pancreatic adenocarcinoma were excluded. Four fellowship-trained abdominal radiologists, blinded to CT type, independently assessed vascular tumor involvement (uninvolved, abuts ≤ 180°, encases > 180°; celiac, superior mesenteric artery (SMA), common hepatic artery (CHA), superior mesenteric vein (SMV), main portal vein), the presence/absence of metastases, overall tumor resectability (resectable, borderline resectable, locally advanced, metastatic), and diagnostic confidence. Fleiss's kappa was used to calculate inter-reader agreement. CTDIvol was recorded. Radiation dose metrics were compared with a two-sample t-test. A p < .05 indicated statistical significance.
results145 patients (71 men, mean[SD] age: 66[9] years) were included. There was substantial inter-reader agreement, for celiac artery, SMA, and SMV involvement at PCCT (kappa = 0.61-0.69) versus moderate agreement at EID-CT (kappa = 0.56-0.59). CHA had substantial inter-reader agreement at both PCCT (kappa = 0.67) and EIDCT (kappa = 0.70). For metastasis identification, radiologists had substantial inter-reader agreement at PCCT (kappa = 0.78) versus moderate agreement at EID-CT (kappa = 0.56). CTDIvol for PCCT and EID-CT were 16.9[7.4]mGy and 29.8[26.6]mGy, respectively (p < .001).
conclusionThere was substantial inter-reader agreement for involvement of 4/5 major peripancreatic vessels (celiac artery, SMA, CHA, and SMV) at PCCT compared with 2/5 for EID-CT. PCCT also afforded substantial inter-reader agreement for metastasis detection versus moderate agreement at EID-CT with statistically significant radiation dose reduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.